Ovarian cancer vaccine trials and tribulations

Bibliography

• DISAIA PJ: Overview of tumor immunology in gynecologic oncology. Cancer (1976) 38(1 Suppl.):566-580.
   PubMed Web of Science ®Google Scholar
• SCHLIENGER K, CHU CS, WOO EY et al.: TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for. Clin. Cancer Res. (2003) 9(4):1517-1527.
   PubMed Web of Science ®Google Scholar
• ZHANG L, CONEJO-GARCIA JR, KATSAROS D et al.: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.[see comment]. N. Engl. J. Med. (2003) 348(3):203-213.
   PubMed Web of Science ®Google Scholar
• SATO E, OLSON SH, AHN J et al.: Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl Acad. Sci. USA (2005) 102(51):18538-18543.
   PubMed Web of Science ®Google Scholar
• BEREK JS, SCHULTES BC, NICODEMUS CF: Biologic and immunologic therapies for ovarian cancer. J. Clin. Oncol. (2003) 21(10S):168s-174s.
   Web of Science ®Google Scholar
• THIGPEN JT, BERTELSEN K, EISENHAUER EA et al.: Long-term follow-up of patients with advanced ovarian carcinoma treated with chemotherapy. Ann. Oncol. (1993) 4(Suppl. 4):35-40.
   PubMed Web of Science ®Google Scholar
• CREASMAN WT, OMURA GA, BRADY MF et al.: A randomized trial of cyclophosphamide, doxorubicin, and cisplatin with or without bacillus Calmette-Guerin in patients with suboptimal stage III and IV ovarian cancer: a Gynecologic Oncology Group study. Gynecol. Oncol. (1990) 39(3):239-243.
   PubMed Web of Science ®Google Scholar
• ALBERTS DS, MASON-LIDDIL N, O’TOOLE RV et al.: Randomized Phase III trial of chemoimmunotherapy in patients with previously untreated stages III. Gynecol. Oncol. (1989) 32(1):8-15.
   PubMed Web of Science ®Google Scholar
• WILBUR DW, RENTSCHLER RE, WAGNER RJ et al.: Randomized trial of the addition of cis-platin (DDP) and/or BCG to cyclophosphamide (CTX). J. Surg. Oncol. (1987) 34(3):165-169.
   PubMed Web of Science ®Google Scholar
• GIUNTOLI RL 2ND, RODRIGUEZ GC, WHITAKER RS et al.: Mucin gene expression in ovarian cancers. Cancer Res. (1998) 58(23):5546-5550.
   PubMed Web of Science ®Google Scholar
• DONG Y, WALSH MD, CUMMINGS MC et al.: Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours. J. Pathol. (1997) 183(3):311-317.
   PubMed Web of Science ®Google Scholar
• SEREGNI E, BOTTI C, BAJETTA E et al.: Hormonal regulation of MUC1 expression. Int. J. Biol. Markers (1999) 14(1):29-35.
   PubMed Web of Science ®Google Scholar
• ZHANG S, ZHANG HS, CORDON-CARDO C et al.: Selection of tumor antigens as targets for immune attack using immunohistochemistry: protein antigens. Clin. Cancer Res. (1998) 4(11):2669-2676.
   Google Scholar
• MUNSTER DJ, QUIN RJ, BANSAL AS et al.: Peritoneal fluid from ovarian cancer patients stimulates MUC1 epithelial mucin expression in ovarian cancer cell lines. Int. J. Cancer (1998) 76(3):393-398.
   PubMed Web of Science ®Google Scholar
• HOLMBERG LA, SANDMAIER B: Vaccination as a treatment for breast or ovarian cancer. Expert Rev. Vaccines (2004) 3(3):269-277.
   PubMedGoogle Scholar
• SANDMAIER BM, OPARIN DV, HOLMBERG LA et al.: Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after. J. Immunother. (1999) 22(1):54-66.
   PubMed Web of Science ®Google Scholar
• BAST R, KLUG T, ST JOHN E et al.: A Radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med. (1983) 309:883-887.
   PubMed Web of Science ®Google Scholar
• REDMAN C, BRADGATE MG, ROLLASON TP et al.: Cancer antigen CA125 in epithelial ovarian cancer: immunohistochemical expression before and after chemotherapy. Eur. J. Cancer Clin. Oncol. (1988) 24(8):1381-1382.
   PubMedGoogle Scholar
• MACDONALD F, BIRD R, STOKES H et al.: Expression of CEA, CA125, CA19-9 and human milk fat globule membrane antigen in ovarian tumours. J. Clin. Pathol. (1988) 41(3):260-264.
   PubMed Web of Science ®Google Scholar
• DALGLEISH AG, KENNEDY RC: Anti-idiotypic antibodies as immunogens: idiotype-based vaccines. [Erratum appears in Vaccine (1988) 6(4):381]. Vaccine (1988) 6(3):215-220.
   PubMed Web of Science ®Google Scholar
• KENNEDY RC, ZHOU EM, LANFORD RE et al.: Possible role of anti-idiotypic antibodies in the induction of tumor immunity. J. Clin. Invest. (1987) 80(5):1217-1224.
   PubMed Web of Science ®Google Scholar
• SCHULTES BC, BAUM RP, NIESEN A, NOUJAIM AA, MADIYALAKAN R: Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1). Cancer Immunol. Immunother. (1998) 46(4):201-212.
   PubMed Web of Science ®Google Scholar
• REINARTZ S, KOHLER S, SCHLEBUSCH H et al.: Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125. Clin. Cancer Res. (2004) 10(5):1580-1587.
   PubMed Web of Science ®Google Scholar
• NOUJAIM AA, SCHULTES BC, BAUM RP et al.: Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13-evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo. Cancer Biother. Radiopharm. (2001) 16(3):187-203.
   PubMed Web of Science ®Google Scholar
• MA J, SAMUEL J, KWON GS et al.: Induction of anti-idiotypic humoral and cellular immune responses by a murine monoclonal antibody recognizing the ovarian carcinoma antigen CA125 encapsulated in biodegradable microspheres. Cancer Immunol. Immunother. (1998) 47(1):13-20.
   PubMed Web of Science ®Google Scholar
• MADIYALAKAN R, SYKES TR, DHARAMPAUL S et al.: Antiidiotype induction therapy: evidence for the induction of immune response through the idiotype network in patients with ovarian cancer after administration of anti-CA125 murine monoclonal antibody B43.13. Hybridoma (1995) 14(2):199-203.
   PubMed Web of Science ®Google Scholar
• EHLEN TG, HOSKINS PJ, MILLER D et al.: A pilot Phase II study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. Int. J. Gynecol. Cancer (2005) 15(6):1023-1034.
   Google Scholar
• NICODEMUS CF, BEREK JS: Monoclonal antibody therapy of ovarian cancer. Expert Rev. Anticancer Ther. (2005) 5(1):87-96.
   PubMed Web of Science ®Google Scholar
• GORDON AN, SCHULTES BC, GALLION H et al.: CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients. Gynecol. Oncol. (2004) 94(2):340-351.
   PubMed Web of Science ®Google Scholar
• BEREK JS, TAYLOR PT, GORDON A et al.: Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J. Clin. Oncol. (2004) 22(17):3507-3516.
   PubMed Web of Science ®Google Scholar
• DE BONO JS, RHA SY, STEPHENSON J et al.: Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity. Ann. Oncol. (2004) 15(12):1825-1833.
   PubMed Web of Science ®Google Scholar
• NICHOLSON S, BOMPHRAY CC, THOMAS H et al.: A Phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunol. Immunother. (2004) 53(9):809-816.
   PubMed Web of Science ®Google Scholar
• ZAROUR HM, STORKUS WJ, BRUSIC V et al.: NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. Cancer Res. (2000) 60(17):4946-4952.
   PubMed Web of Science ®Google Scholar
• SOLING A, SCHURR P, BERTHOLD F et al.: Expression and clinical relevance of NY-ESO-1, MAGE-1 and MAGE-3 in neuroblastoma. Anticancer Res. (1999) 19(3B):2205-2209.
   PubMed Web of Science ®Google Scholar
• CHEN YT, SCANLAN MJ, SAHIN U et al.: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl Acad. Sci. USA (1997) 94(5):1914-1918.
   PubMed Web of Science ®Google Scholar
• VALMORI D, DUTOIT V, LIENARD D et al.: Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res. (2000) 60(16):4499-4506.
   PubMed Web of Science ®Google Scholar
• SCHULTZ-THATER E, NOPPEN C, GUDAT F et al.: NY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimens. Br. J. Cancer (2000) 83(2):204-208.
   PubMed Web of Science ®Google Scholar
• JAGER E, JAGER D, KARBACH J et al.: Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J. Exp. Med. (2000) 191(4):625-630.
   PubMed Web of Science ®Google Scholar
• ODUNSI K, QIAN F, GNJATIC S et al.: Immunization of ovarian cancer patients with an NY-ESO-1 peptide of dual MHC class I and II specificities plus incomplete Freund adjuvant induces simultaneous humoral, CD4+ and CD8+ T-cell responses. ASCO Meeting Abstracts (2005) 23(16 Suppl.):Abstract 5040.
   Google Scholar
• QIAN F, GNJATIC S, JAGER E et al.: Th1/Th2 CD4+ T cell responses against NY-ESO-1 in HLA-DPB1*0401/0402 patients with epithelial ovarian cancer. Cancer Immunity (2004) 4:12.
   PubMedGoogle Scholar
• SLAMON DJ, CLARK GM: Amplification of c-erbB-2 and aggressive human breast tumors? Science (1988) 240(4860):1795-1798.
   PubMed Web of Science ®Google Scholar
• SLAMON DJ: Proto-oncogenes and human cancers. N. Engl. J. Med. (1987) 317(15):955-957.
   PubMed Web of Science ®Google Scholar
• DISIS M, CHEEVER M: HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv. Cancer Res. (1997) 71:343-371.
   PubMed Web of Science ®Google Scholar
• DISIS ML, GOOLEY TA, RINN K et al.: Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J. Clin. Oncol. (2002) 20(11):2624-2632.
   Google Scholar
• PEOPLES GE, GURNEY JM, HUEMAN MT et al.: Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J. Clin. Oncol. (2005) 23(30):7536-7545.
   PubMed Web of Science ®Google Scholar
• SLAMON DJ, GODOLPHIN W, JONES LA et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 244(4905):707-712.
   PubMed Web of Science ®Google Scholar
• CARBONE DP, CIERNIK IF, KELLEY MJ et al.: Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. J. Clin. Oncol. (2005) 23(22):5099-5107.
   PubMed Web of Science ®Google Scholar
• PAVLENKO M, LEDER C, PISA P et al.: Plasmid DNA vaccines against cancer: cytotoxic T-lymphocyte induction against tumor antigens. Expert Rev. Vaccines (2005) 4(3):315-327.
   PubMed Web of Science ®Google Scholar
• CUI Z, DIERLING A, FOLDVARI M et al.: Non-invasive immunization on the skin using DNA vaccine. Curr. Drug Deliv. (2006) 3(1):29-35.
   PubMedGoogle Scholar
• KUTZLER MA, WEINER DB: Developing DNA vaccines that call to dendritic cells. J. Clin. Invest. (2004) 114(9):1241-1244.
   PubMed Web of Science ®Google Scholar
• GIULIANO AE, RANGEL D, GOLUB SH et al.: Serum-mediated immunosuppression in lung cancer. Cancer (1979) 43(3):917-924.
   PubMed Web of Science ®Google Scholar
• GAJEWSKI TF, MENG Y, HARLIN H et al.: Immune suppression in the tumor microenvironment. J. Immunother. (2006) 29(3):233-240.
   PubMed Web of Science ®Google Scholar
• BANCHEREAU J, PALUCKA AK: Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. (2005) 5(4):296-306.
   PubMed Web of Science ®Google Scholar
• HERNANDO JJ, PARK T-W, KUBLER K et al.: Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological. Cancer Immunol. Immunother. (2002) 51(1):45-52.
   PubMed Web of Science ®Google Scholar
• KOIDO S, NIKRUI N, OHANA M et al.: Assessment of fusion cells from patient-derived ovarian carcinoma cells and dendritic cells as a vaccine for clinical use. Gynecol. Oncol. (2005) 99(2):462-471.
   PubMed Web of Science ®Google Scholar
• MARSHALL JL, GULLEY JL, ARLEN PM et al.: Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J. Clin. Oncol. (2005) 23(4):720-731.
   Google Scholar
• KIRKWOOD JM, ERNSTOFF MS: Interferons in the treatment of human cancer. J. Clin. Oncol. (1984) 2(4):336-352.
   Google Scholar
• GARBE C: Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma. Melanoma Res. (1993) 3(4):291-299.
   PubMed Web of Science ®Google Scholar
• CHARAK BS, SADOWSKI RM, MAZUMDER A et al.: Antitumor effect of interferon plus cyclosporine A following chemotherapy for disseminated melanoma. Cancer Res. (1992) 52(23):6482-6486.
   PubMed Web of Science ®Google Scholar
• NICOLETTO MO, FIORENTINO MV, VINANTE O et al.: Experience with intraperitoneal alpha-2a interferon. Oncology (1992) 49(6):467-473.
   PubMed Web of Science ®Google Scholar
• BEREK JS: Interferon plus chemotherapy for primary treatment of ovarian cancer. Lancet (2000) 356(9223):6-7.
   PubMed Web of Science ®Google Scholar
• WALL L, BURKE F, SMYTH JF, BALKWILL F: The anti-proliferative activity of interferon-gamma on ovarian cancer: in vitro and in vivo. Gynecol. Oncol. (2003) 88(1 Pt 2):S149-S151.
   PubMed Web of Science ®Google Scholar
• ALBERTS DS, HANNIGAN EV, LIU PY et al.: Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: an intergroup study. Gynecol. Oncol. (2006) 100(1):133-138.
   PubMed Web of Science ®Google Scholar
• KURBACHER CM, KURBACHER JA, CRAMER EM et al.: Continuous low-dose GM-CSF as salvage therapy in refractory recurrent breast or female genital tract carcinoma. Oncology (Huntington) (2005) 19(4 Suppl. 2):23-26.
   PubMed Web of Science ®Google Scholar
• NEMUNAITIS J: Vaccines in cancer: GVAX, a GM-CSF gene vaccine. Expert Rev. Vaccines (2005) 4(3):259-274.
   PubMed Web of Science ®Google Scholar
• DONG H, CHEN L: B7-H1 pathway and its role in the evasion of tumor immunity. J. Mol. Med. (2003) 81(5):281-287.
   PubMed Web of Science ®Google Scholar
• KRYCZEK I, ZOU L, RODRIGUEZ P et al.: B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma.[see comment]. J. Exp. Med. (2006) 203(4):871-881.
   PubMed Web of Science ®Google Scholar
• WEI S, KRYCZEK I, ZOU L et al.: Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res. (2005) 65(12):5020-5026.
   PubMed Web of Science ®Google Scholar
• SANTIN AD, BELLONE S, RAVAGGI A et al.: Increased levels of interleukin-10 and transforming growth factor-beta in the plasma and ascitic fluid of patients with advanced ovarian cancer. BJOG (2001) 108(8):804-808.
   PubMed Web of Science ®Google Scholar
• LOERCHER AE, NASH MA, KAVANAGH JJ et al.: Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells. J. Immunol. (1999) 163(11):6251-6260.
   PubMed Web of Science ®Google Scholar
• ZEIMET AG, WIDSCHWENDTER M, KNABBE C et al.: Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer. J. Clin. Oncol. (1998) 16(5):1861-1868.
   Google Scholar
• MALOY KJ, POWRIE F, MALOY KJ, POWRIE F: Regulatory T cells in the control of immune pathology. Nat. Immunol. (2001) 2(9):816-822.
   PubMed Web of Science ®Google Scholar
• TAAMS LS, PALMER DB, AKBAR AN et al.: Regulatory T cells in human disease and their potential for therapeutic manipulation. Immunology (2006) 118(1):1-9.
   PubMed Web of Science ®Google Scholar
• WOO EY, CHU CS, GOLETZ TJ et al.: Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. (2001) 61(12):4766-4772.
   PubMed Web of Science ®Google Scholar
• CURIEL TJ, COUKOS G, ZOU L et al.: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. (2004) 10(9):942-949.
   PubMed Web of Science ®Google Scholar
• RYAN MH, BRISTOL JA, MCDUFFIE E et al.: Regression of extensive pulmonary metastases in mice by adoptive transfer of antigen-specific CD8(+) CTL reactive against tumor cells expressing a naturally occurring rejection epitope. J. Immunol. (2001) 167(8):4286-4292.
   PubMed Web of Science ®Google Scholar
• ZHENG P, WU Y, GUO Y et al.: B7-CTLA4 interaction enhances both production of antitumor cytotoxic T lymphocytes and resistance to tumor challenge. Proc. Natl Acad. Sci. USA (1998) 95(11):6284-6289.
   PubMed Web of Science ®Google Scholar
• PEGGS KS, QUEZADA SA, KORMAN AJ et al.: Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr. Opin. Immunol. (2006) 18(2):206-213.
   PubMed Web of Science ®Google Scholar
• ATTIA P, PHAN GQ, MAKER AV et al.: Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. (2005) 23(25):6043-6053.
   Google Scholar
• HODI FS, MIHM MC, SOIFFER RJ et al.: Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl Acad. Sci. USA (2003) 100(8):4712-4717.
   PubMed Web of Science ®Google Scholar
• DIRKX AE, OUDE EGBRINK MG, KUIJPERS MJ et al.: Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res. (2003) 63(9):2322-2329.
   PubMed Web of Science ®Google Scholar
• KATAKI A, SCHEID P, PIET M et al.: Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression. J. Lab. Clin. Med. (2002) 140(5):320-328.
   PubMed Web of Science ®Google Scholar
• BUCKANOVICH RJ, KIM S, BENENCIA F et al.: Endothelin receptor B predicts poor prognosis in epithelial ovarian cancer (EOC) and can be inhibited to increase intratumoral T cells and enhance tumor vaccine therapy. ASCO Meeting Abstracts (2006) 24(18 Suppl.):2524.
   Google Scholar
• GURULI G, PFLUG BR, PECHER S et al.: Function and survival of dendritic cells depend on endothelin-1 and endothelin receptor autocrine loops. Blood (2004) 104(7):2107-2115.
   PubMed Web of Science ®Google Scholar
• MEDINGER M, ADLER CP, SCHMIDT-GERSBACH C et al.: Angiogenesis and the ET-1/ETA receptor system: immunohistochemical expression analysis in bone metastases from patients with different primary tumors. Angiogenesis (2003) 6(3):225-231.
   PubMedGoogle Scholar
• GRIMSHAW MJ, WILSON JL, BALKWILL FR: Endothelin-2 is a macrophage chemoattractant: implications for macrophage distribution in tumors. Eur. J. Immunol. (2002) 32(9):2393-2400.
   PubMed Web of Science ®Google Scholar
• SAMPAIO AL, RAE GA, HENRIQUES MM: Role of endothelins on lymphocyte accumulation in allergic pleurisy. J. Leukoc. Biol. (2000) 67(2):189-195.
   PubMed Web of Science ®Google Scholar
• HIGANO CS, BURCH PA, SMALL EJ et al.: Immunotherapy (APC8015) for androgen independent prostate cancer (AIPC): final progression and survival data from a second Phase III trial. 13th European Cancer Conference. Paris, France (30 October – 3 November 2005) Abstract PS1.
   Google Scholar
• SMALL EJ, SCHELLHAMMER PF, HIGANO CS et al.: Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. (2006) 24:3089-3094.
   PubMed Web of Science ®Google Scholar
• BUCKANOVICH RJ, SASAROLI D, O’BRIEN-JENKINS A et al.: Tumor vascular proteins as biomarkers in ovarian cancer. J. Clin. Oncol. (2006) (In Press).
   Google Scholar
• NANDA A, ST CROIX B: Tumor endothelial markers: new targets for cancer therapy. Curr. Opin. Oncol. (2004) 16(1):44-49.
   PubMed Web of Science ®Google Scholar
• ALBERT ML, DARNELL RB: Paraneoplastic neurological degenerations: keys to tumour immunity. Nat. Rev. Cancer (2004) 4(1):36-44.
   PubMed Web of Science ®Google Scholar
• BUCKANOVICH RJ, POSNER JB, DARNELL RB: Nova, the paraneoplastic Ri antigen, is homologous to an RNA-binding protein and is specifically expressed in the developing motor system. Neuron (1993) 11(4):657-672.
   PubMed Web of Science ®Google Scholar